Anil Chhettry from Carlsbad, CA, age 63

Name / Title

Company / Classification

Phones & Addresses

Anil Chhettry
Assistant Director

Forest Research Institute, Inc
Noncommercial Research Organization

49 Mall Dr, Commack, NY 11725
(631)8585230

Lercanidipine Immediate Release Compositions
view source
US Patent:

20060134212, Jun 22, 2006
Filed:

Sep 2, 2005
Appl. No.:

11/218820
Inventors:

Mahendra Dedhiya - Pomona NY, US
Suneel Rastogi - Ballwin MO, US
Anil Chhettry - Holtsville NY, US
Assignee:

Forest Laboratories, Inc. - New York NY
International Classification:

A61K 31/445
A61K 9/24
US Classification:

424472000, 514317000
Abstract:

The present invention provides an immediate release composition for the low solubility drug, lercanidipine. The immediate release composition of the present invention comprises a core; a first layer, comprising lercanidipine, a surfactant and a binder, and optionally, a second layer comprising a film coating.

Lercanidipine Ph Dependent Pulsatile Release Compositions
view source
US Patent:

20060165788, Jul 27, 2006
Filed:

Sep 9, 2005
Appl. No.:

11/223491
Inventors:

Wattanaporn Abramowitz - West Windsor NJ, US
Ram Kapil - Princeton Junction NJ, US
Todd Riccobene - Basking Ridge NJ, US
Mahendra Dedhiya - Pomona NY, US
Suneel Rastogi - Ballwin MO, US
Anil Chhettry - Holtsville NY, US
International Classification:

A61K 31/445
A61K 9/22
US Classification:

424468000, 514317000
Abstract:

Pursuant to the present invention it has been found that a modified release composition containing the low solubility and permeability drug, lercanidipine may be prepared that provides for therapeutically effective plasma concentrations of lercanidipine for 24 hours. The modified release composition of the present invention release pulses of lercanidipine based on the pH of the use environment. An effective quantity of dissolved lercanidipine is released throughout the GI Tract.

Lercanidipine Modified Release Compositions
view source
US Patent:

20060165789, Jul 27, 2006
Filed:

Sep 9, 2005
Appl. No.:

11/223493
Inventors:

Wattanaporn Abramowitz - West Windsor NJ, US
Ram Kapil - Princeton Junction NJ, US
Todd Riccobene - Basking Ridge NJ, US
Mahendra Dedhiya - Pomona NY, US
Yan Yang - Roslyn Heights NY, US
Anil Chhettry - Holtsville NY, US
Assignee:

Forest Laboratories, Inc. - New York NY
International Classification:

A61K 31/445
A61K 9/22
US Classification:

424468000, 514317000
Abstract:

Pursuant to the present invention, it has been found that a modified release composition containing the low permeability and poor solubility drug, lercanidipine, may be prepared which provides for therapeutically effective plasma concentrations of lercanidipine for a period of about 20 to about 25 hours. The modified release composition of the present invention provides modified release of lercanidipine independent of pH and therefore provides release of lercanidipine even upon exposure to the low pH use environments, such as gastric fluid.

Modified And Immediate Release Formulations Of Memantine
view source
US Patent:

20070065512, Mar 22, 2007
Filed:

Jun 14, 2006
Appl. No.:

11/424024
Inventors:

Mahendra Dedhiya - Pomona NY, US
Suneel Rastogi - Ballwin MO, US
Anil Chhettry - Holtsville NY, US
Narasimhan Mani - Morris Plains NJ, US
Antonia Periclou - Jersey City NJ, US
Niranjan Rao - Belle Mead NJ, US
Assignee:

Forest Laboratories, Inc. - New York NY
International Classification:

A61K 9/26
A61K 31/13
US Classification:

424469000, 514662000
Abstract:

The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.

Stable Pharmaceutical Formulations Containing Escitalopram And Bupropion
view source
US Patent:

20070112075, May 17, 2007
Filed:

Oct 16, 2006
Appl. No.:

11/582164
Inventors:

Mahendra Dedhiya - Pomona NY, US
Anil Chhettry - Holtsville NY, US
Narasimhan Mani - Morris Plains NJ, US
Assignee:

Forest Laboratories, Inc. - New York NY
International Classification:

A61K 31/138
US Classification:

514651000
Abstract:

The present invention relates to stable pharmaceutical formulations of escitalopram and bupropion and their use for the treatment a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, or panic disorder).

Modified And Pulsatile Release Pharmaceutical Formulations Of Escitalopram
view source
US Patent:

20070134322, Jun 14, 2007
Filed:

Dec 13, 2006
Appl. No.:

11/610194
Inventors:

Mahendra Dedhiya - Pomona NY, US
Anil Chhettry - Holtsville NY, US
Yan Yang - Roslyn Heights NY, US
Assignee:

Forest Laboratories, Inc. - New York NY
International Classification:

A61K 9/20
A61K 31/343
US Classification:

424464000, 514469000
Abstract:

The present invention relates to modified and pulsatile release pharmaceutical formulations of escitalopram and their use for the treatment of central nervous system disorders, including mood disorders (e.g., major depressive disorder) and anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder, including panic attacks).

Orally Dissolving Formulations Of Memantine
view source
US Patent:

20080008743, Jan 10, 2008
Filed:

Jul 6, 2007
Appl. No.:

11/774292
Inventors:

Mahendra Dedhiya - Pomona NY, US
Anil Chhettry - Holtsville NY, US
Ranajoy Sarkar - Piscataway NJ, US
Assignee:

Forest Laboratories Holdings Limited - Hamilton
International Classification:

A61K 9/70
A61K 31/13
A61P 25/00
A61P 43/00
A61K 9/22
US Classification:

424443000, 424468000, 514662000
Abstract:

Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.

Pharmaceutical Formulations Containing Dopamine Receptor Ligands
view source
US Patent:

20100016334, Jan 21, 2010
Filed:

Jul 16, 2009
Appl. No.:

12/504149
Inventors:

Ranajoy SARKAR - Piscataway NJ, US
Mahendra G. DEDHIYA - Pomona NY, US
Anil CHHETTRY - Holtsville NY, US
International Classification:

A61K 31/495
C07D 295/135
US Classification:

51425503, 544393
Abstract:

The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.